Emedastine Difumarate Patent Expiration
Emedastine Difumarate is Used for treating allergic conjunctivitis. It was first introduced by Novartis Pharmaceuticals Corp
Emedastine Difumarate Patents
Given below is the list of patents protecting Emedastine Difumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Emadine | US5441958 | Ophthalmic compositions comprising emedastine and methods for their use |
Dec 08, 2013
(Expired) | Novartis |
Emedastine Difumarate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Emedastine Difumarate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| This Phase 1a Study Will Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Relative Bioavailability of Single-dose DMI019 Nasal Spray in Healthy Participants. | The Third Xiangya Hospital of Central South University | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |